David Tulasne

8PUBLICATIONS
27CO-AUTHORS
Molecular targetsOncology and carcinogenesis not elsewhere classifiedPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 08, 2026
Targeting Both Oncogenic Signaling and Dependence Receptor Function is Required to Fully Suppress MET Exon 14 Skipping-Driven tumorigenesis.

|Nov 03, 2025
Comprehensive map of the regulatory network triggered by MET exon 14 skipping reveals important involvement of the RAS-ERK signaling pathway.

Marie-José Truong, Geoffrey Pawlak, Jean-Pascal Meneboo

|Feb 21, 2025
MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation.

Célia Guérin, Audrey Vinchent, Marie Fernandes

|Oct 07, 2024
Functional interaction between receptor tyrosine kinase MET and ETS transcription factors promotes prostate cancer progression.

Elisa Carouge, Clémence Burnichon, Martin Figeac

|Apr 23, 2024
Recording and classifying MET receptor mutations in cancers.

Célia Guérin, David Tulasne

|Jul 19, 2023
Transforming properties of MET receptor exon 14 skipping can be recapitulated by loss of the CBL ubiquitin ligase binding site.

Marie Fernandes, Sonia Paget, Zoulika Kherrouche

Pageof 2

Frequent Collaborators

2 joint publications

Anne Chotteau-Lelièvre

2 joint publications

Marie-José Truong

1 joint publications

Leslie Duplaquet

1 joint publications

Fabien Vanden Abeele